Literature DB >> 15233757

Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model.

Tatsuo Yamamoto1, Serabi Hirasawa, Barbara Wroblewska, Ewa Grajkowska, Jia Zhou, Alan Kozikowski, Jarda Wroblewski, Joseph H Neale.   

Abstract

The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) acts as an agonist at group II metabotropic glutamate receptors (mGluRs). NAAG is inactivated by extracellular peptidase activity yielding glutamate and N-acetylaspartate. We recently developed a series of potent NAAG peptidase inhibitors, including ZJ-11, ZJ-17 and ZJ-43. In the present study, we examined the effects of intrathecally administered ZJ-11 and ZJ-17 and intravenously administered ZJ-11 and ZJ-43 in the rat formalin test (an inflammatory pain model) and in the rat partial sciatic nerve ligation model (a neuropathic pain model). Intrathecal injection of ZJ-11 or ZJ-17 or intravenous injection of ZJ-11 or ZJ-43 suppressed both phases of the agitation behaviour induced by paw formalin injection. Intrathecal and intravenous injection of ZJ-11 suppressed the expression of Fos-like immunoreactivity, induced by paw formalin injection, in laminae I-II in segments L4-L5 of the spinal cord, suggesting an action on sensory spinal transmission. Partial sciatic nerve ligation induced significant mechanical allodynia 7 days after the nerve injury. Intrathecal injection of ZJ-11 or ZJ-17 or intravenous administration of ZJ-11 or ZJ-43 attenuated the level of mechanical allodynia induced by this nerve ligation. These effects of intrathecally or intravenously administered ZJ compounds in both the formalin test and the partial sciatic nerve ligation model were completely antagonized by pretreatment with LY-341495, a highly selective group II mGluR antagonist. Thus, elevation of extracellular NAAG, induced by the inhibition of NAAG peptidase, activates group II mGluRs and produces an analgesic effect in neuropathic and inflammatory and pain models. In contrast, peptidase inhibition did not affect the threshold for withdrawal from a noxious mechanical stimulus or from an acute thermal stimulus in the hotplate test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233757     DOI: 10.1111/j.1460-9568.2004.03504.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  34 in total

1.  Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI.

Authors:  Jun-Feng Feng; Ken C Van; Gene G Gurkoff; Christina Kopriva; Rafal T Olszewski; Minsoo Song; Shifeng Sun; Man Xu; Joseph H Neale; Po-Wai Yuen; David A Lowe; Jia Zhou; Bruce G Lyeth
Journal:  Brain Res       Date:  2011-04-20       Impact factor: 3.252

Review 2.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.

Authors:  Raag D Airan; Catherine A Foss; Nicholas P K Ellens; Yuchuan Wang; Ronnie C Mease; Keyvan Farahani; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

Review 4.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

Review 5.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 6.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

7.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

8.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

9.  NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.

Authors:  Karolina J Janczura; Rafal T Olszewski; Tomasz Bzdega; Dean J Bacich; Warren D Heston; Joseph H Neale
Journal:  Eur J Pharmacol       Date:  2012-11-29       Impact factor: 4.432

10.  Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.

Authors:  James J Vornov; Krystyna M Wozniak; Ying Wu; Camilo Rojas; Rana Rais; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2013-06-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.